Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04331626
Other study ID # 2019090507
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date April 2020
Est. completion date April 2023

Study information

Verified date December 2019
Source Henan Cancer Hospital
Contact Zibing Wang, Doctor
Phone +8610 037165587483
Email zlyywzb2118@zzu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In recent years, immunotherapy research has made great progress, especially the immunocheckpoint inhibitors represented by anti-pd-1 antibody have shown good efficacy in the treatment of malignant tumors, and some patients can achieve long-term survival. However, despite the encouraging clinical data, only a small number of people have benefited. Therefore, how to further improve the efficacy of immunotherapy and expand the benefit population has become the focus of this field.

The applicant was previously published in Oncoimmunology (2017; E1331807) pointed out in the above article: MDSC is a group of immunosuppressive cells, the number of this group of cells in the body of cancer patients is more than normal, its presence affects the proliferation, activation and function of T cells, is one of the important factors affecting the efficacy of immunocheckpoint inhibitors. Therefore, ideal drugs used in combination with immunocheckpoint inhibitors should meet the following conditions: first, they can kill or inactivate tumor cells to release tumor-specific or associated antigens; Second, MDSC and other immunosuppressive cells can be eliminated. Third, the number and function of T cells were not affected.

Gemcitabine is a synthetic antimetabolic tumor drug widely used in the treatment of locally advanced or metastatic non-small cell lung cancer. Myelosuppression is the dose - limiting toxicity of gemcitabine, which includes lymphocytopenia. Therefore, if the commonly used clinical dose gemcitabine is used in combination with pd-1 antibody, the effect of pd-1 antibody will be affected due to the reduction of lymphocytes caused by gemcitabine. Therefore, we speculated that the reduced-dose treatment of gemcitabine combined with pd-1 antibody might have synergistic anti-tumor effect on the second-line and above second-line treatment of non-small cell lung cancer with negative driver gene, and the adverse reactions were relatively mild.

This study is a phase IV, open, non-randomized, single-arm, single-center study to investigate the safety and efficacy of half-dose gemcitabine combined with pd-1 antibody in second-line and above treatment of non-small cell lung cancer patients with negative driver genes. Fifty subjects will be enrolled in this study. The primary endpoint of the study was ORR, while secondary endpoints included DCR, PFS, and OS.


Description:

In recent years, immunotherapy research has made great progress, especially the immunocheckpoint inhibitors represented by anti-pd-1 antibody have shown good efficacy in the treatment of malignant tumors, and some patients can achieve long-term survival. However, despite the encouraging clinical data, only a small number of people have benefited. Therefore, how to further improve the efficacy of immunotherapy and expand the benefit population has become the focus of this field.

Conventional view holds that chemotherapeutic drugs work by directly killing tumor cells. In recent years, with the in-depth understanding of immunity, people have realized that the anti-cancer effect of chemotherapy drugs depends on the body's sound immune system, and chemotherapy drugs have been more and more recognized as an immune regulator. However, it should be noted that the combination of drugs may not achieve the desired results, or even the opposite.

The applicant was previously published in Oncoimmunology (2017; E1331807) pointed out in the above article: MDSC is a group of immunosuppressive cells, the number of this group of cells in the body of cancer patients is more than normal, its presence affects the proliferation, activation and function of T cells, is one of the important factors affecting the efficacy of immunocheckpoint inhibitors. Therefore, ideal drugs used in combination with immunocheckpoint inhibitors should meet the following conditions: first, they can kill or inactivate tumor cells to release tumor-specific or associated antigens; Second, MDSC and other immunosuppressive cells can be eliminated. Third, the number and function of T cells were not affected.

Gemcitabine is a synthetic antimetabolic tumor drug widely used in the treatment of locally advanced or metastatic non-small cell lung cancer. Myelosuppression is the dose - limiting toxicity of gemcitabine, which includes lymphocytopenia. Therefore, if the commonly used clinical dose gemcitabine is used in combination with pd-1 antibody, the effect of pd-1 antibody will be affected due to the reduction of lymphocytes caused by gemcitabine. Therefore, we speculated that the reduced-dose treatment of gemcitabine combined with pd-1 antibody might have synergistic anti-tumor effect on the second-line and above second-line treatment of non-small cell lung cancer with negative driver gene, and the adverse reactions were relatively mild.

This study is a phase IV, open, non-randomized, single-arm, single-center study to investigate the safety and efficacy of half-dose gemcitabine combined with pd-1 antibody in second-line and above treatment of non-small cell lung cancer patients with negative driver genes. Fifty subjects will be enrolled in this study. The primary endpoint of the study was objective efficiency (ORR), while secondary endpoints included disease control rate (DCR), disease-free progression (PFS), and overall survival (OS).


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date April 2023
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- the patient voluntarily participated in the study and signed the informed consent;

- advanced non-small cell lung cancer with negative driving gene confirmed by pathology has at least one measurable focus.

- in the last 6 months, chemotherapy failed;

- 18-70 years old; ECoG PS score 0-1; estimated survival time over 3 months;

- within 7 days before treatment, the main organ functions meet the following standards:

1. blood routine examination standard (without blood transfusion within 14 days):

A) hemoglobin (HB) = 90g / L;

B) neutrophil absolute value (ANC) = 1.5 × 109 / L;

C) platelet (PLT) = 80 × 109 / L

2. biochemical examination shall meet the following standards:

A) TBIL = 1.5 times the upper limit of normal value (ULN);

B) ALT and AST = 2.5 × ULN, if with liver metastasis, ALT and AST = 5 × ULN;

C) Cr = 1.5 × ULN or CCR = 60ml / min;

3. Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) = the lower limit of normal value (50%).

- women of childbearing age shall agree to use contraceptive measures (such as IUD, contraceptive pill or condom) during the study and within 6 months after the end of the study; women of childbearing age shall agree to use contraceptive measures during the study and within 6 months after the end of the study (such as IUD, contraceptive pill or condom); women of childbearing age shall agree to use contraceptive measures during the study and 6 months after the end of the study if their pregnancy test is negative within 7 days before the study.

Exclusion Criteria:

- patients who have used PD-1 antibody of other companies before;

- with pleural effusion or ascites, it causes respiratory syndrome (= CTC AE Level 2 dyspnea);

- unresponsive toxic reactions higher than level 1 of CTC AE (4.0) caused by any previous treatment, excluding hair loss;

- patients with any serious and / or uncontrolled disease, including:

1. patients with myocardial ischemia or myocardial infarction above grade I, arrhythmia (including QTc = 480ms) and congestive heart failure = grade 2 (NYHA classification);

2. active or uncontrollable severe infection (= CTC AE Level 2 infection);

3. renal failure needs hemodialysis or peritoneal dialysis;

- patients with any serious and / or uncontrolled disease, including:

1. have a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation;

2. poor control of diabetes mellitus (FBG > 10mmol / L);

3. routine urine test indicated that urine protein was = + +, and 24-hour urine protein was more than 1.0 G;

4. patients with epilepsy who need treatment;

- received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before the group;

- those who have a history of psychoactive drug abuse and are unable to quit or have mental disorders;

- participated in clinical trials of other anti-tumor drugs within four weeks;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gemcitabine Injectable Product
Low dose chemotherapy drug combined with pd-1 antibody, Gemcitabine should be administered at 50% of the recommended dose, i.e. 500mg/m2, for 30 minutes by intravenous drip. Day 1 and day 8 administration.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Henan Cancer Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Objective response rate (ORR) The proportion of patients whose tumor volume reduction reaches the predetermined value and can maintain the minimum time limit is the sum of the proportion of complete and partial remission. 3 months
Secondary Disease control rate The percentage of patients with PR + Cr and SD after treatment in the number of evaluable cases, and the RECIST standard is at least 4 weeks. 3 years
Secondary disease free progression The time from the beginning of treatment to the occurrence (in any respect) progression or (for any reason) death of the tumor. 3 years
Secondary overall survival The time from the beginning of treatment to (for any reason) death. The last follow-up time is usually calculated as the time of death for the subjects who have lost the visit before death. 3 years
See also
  Status Clinical Trial Phase
Completed NCT01523340 - A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Recruiting NCT03956641 - Evolution of the Physical Condition in Treated Cancer Patients N/A
Active, not recruiting NCT02035683 - PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy N/A
Completed NCT01848613 - Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC Phase 4
Suspended NCT01320501 - Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer Phase 4
Terminated NCT01471964 - Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer Phase 1/Phase 2
Recruiting NCT06127940 - K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation Phase 1
Terminated NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Terminated NCT03445000 - ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Phase 2
Terminated NCT03386929 - Survival Prolongation by Rationale Innovative Genomics Phase 1/Phase 2
Recruiting NCT02922764 - A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer Phase 1
Terminated NCT01574300 - Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network
Active, not recruiting NCT04646824 - Almonertinib With Chemotherapy in mEGFR NSCLC Phase 2
Completed NCT01966003 - Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer Phase 3
Recruiting NCT03656094 - Chemotherapy With Pembrolizumab Continuation After Progression to PD-1/L1 Inhibitors Phase 2
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Active, not recruiting NCT03469960 - Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT04793815 - Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE) N/A
Terminated NCT01380795 - Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas Early Phase 1